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Abstract
GPR17 is a Gi-coupled dual receptor activated by uracil-nucleotides and cysteinyl-leukotrienes. These mediators are massively released into
hypoxic tissues. In the normal heart, GPR17 expression has been reported. By contrast, its role in myocardial ischaemia has not yet been
assessed. In the present report, the expression of GPR17 was investigated in mice before and at early stages after myocardial infarction by
using immunofluorescence, flow cytometry and RT-PCR. Before induction of ischaemia, results indicated the presence of the receptor in a pop-
ulation of stromal cells expressing the stem-cell antigen-1 (Sca-1). At early stages after ligation of the coronary artery, the receptor was
expressed in Sca-1+ cells, and cells stained with Isolectin-B4 and anti-CD45 antibody. GPR17+ cells also expressed mesenchymal marker CD44.
GPR17 function was investigated in vitro in a Sca-1+/CD31 cell line derived from normal hearts. These experiments showed a migratory func-
tion of the receptor by treatment with UDP-glucose and leukotriene LTD4, two GPR17 pharmacological agonists. The GPR17 function was
finally assessed in vivo by treating infarcted mice with Cangrelor, a pharmacological receptor antagonist, which, at least in part, inhibited early
recruitment of GPR17+ and CD45+ cells. These findings suggest a regulation of heart-resident mesenchymal cells and blood-borne cellular spe-
cies recruitment following myocardial infarction, orchestrated by GPR17.
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Introduction
The early response to acute myocardial ischaemia (MI) is dominated
by an innate immunity-related process that prevents ventricular rup-
ture through rapid formation of a granulation tissue. This is thereafter
replaced by a collagen-abundant scar [1]. During the inflammatory
phase, the first trigger for recruitment of leucocytes into the infarcted
area is represented by local release of pro-inflammatory mediators.
Neutrophils and macrophages then clear the wound from dead cells
and matrix debris, and produce cytokines/growth factors promoting
myofibroblasts recruitment (MFs) [2–4]. The progressive substitution
of the contractile myocardium with fibrocellular, Collagen-I enriched
and un-contractile tissue results in heart functional alteration; this
condition is called post-ischaemic heart failure [3].
Cellular damage associated with tissue hypoxia causes local and
systemic release of extracellular nucleotides (e.g. ATP/ADP and Ura-
cil-nucleotides UTP/UDP) and Cysteinyl-Leukotrienes (cys-LTs).
Extracellular nucleotides have been classically involved in hypoxic cell
death [5] or cardioprotection [6, 7], whereas Cys-LTs, generated by
5-Lipoxygenase metabolism of Arachidonic acid, play important roles
in priming inflammatory signalling in ischaemic tissues [8–11]. In this
framework, the P2Y-like GPR17 receptor responds to these ligand
families as a dual Gi-coupled receptor, it is expressed in organs sus-
ceptible to ischaemic damage such as the heart, the kidney and the
#Equal contribution.
*Correspondence to: Maurizio PESCE, B.Sc. Ph.D.,
Laboratorio di Ingegneria Tissutale Cardiovascolare,
Centro Cardiologico Monzino, IRCCS,
Via Parea, 4, Milan I-20138,
Italy.
Tel.: +39-02-58002-019
Fax: +39-02-5800-2623
E-mail: maurizio.pesce@ccfm.it
ª 2014 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
doi: 10.1111/jcmm.12305
J. Cell. Mol. Med. Vol 18, No 9, 2014 pp. 1785-1796
brain [12, 13] and it has been recently classified as an oligodendro-
cyte precursors receptor with a potential function in glial cell differen-
tiation [14, 15].
Prompted by a recent appraisal of purinergic signalling in para-
crine activity of cardiac stromal cells [16] and lines of evidence show-
ing a complex function of the GPR17 receptor in brain ischaemic
damage, in the present contribution, we investigated the expression
of the receptor in the mouse heart, before and after MI and partially
assessed its function by in vitro and in vivo studies
Materials and methods
Experimental design of the animal model and
ethical declaration
Experiments were conducted in accordance with institutional guidelines,
conformed to national and international law and policies (4D.L. N.116,
G.U., supplement 40, 18-2-1992; EEC Council Directive 86/609, OJ L
358,1,12-12-1987; National Institutes of Health’s Guide for the Care and
Use of Laboratory Animals and US National Research Council 1996).
C57Bl/6N mice (Charles River Laboratories, Calco, Italy), aged 8 weeks
(18–20 g bw), were fed ad libitum with standard chow/water, and
randomly assigned to two groups: sham-operated mice and MI-mice.
Surgery and sacrifices were performed under anaesthesia with intraperi-
toneal 75 mg/kg ketamine cloridrate and 1 mg/kg medetomidine.
In vivo myocardial infarction/pharmacological
treatments
Mice were anaesthetized, intubated and ventilated with positive airway
pressure. After thoracotomy, MI was induced by permanent ligation of
the left anterior descending coronary artery (LAD) as previously
reported [17]. Sham-operated mice underwent identical surgical proce-
dure without LAD-ligation. Mice (five animals/group/time-point) were
sacrificed at 24 and 48 hrs post-MI for morphological and immunofluo-
rescence (IF) analyses. Further details about surgical procedures, MI
quantification, pharmacological treatments, hearts collection and histo-
logical processing are provided in the online supplementary material.
Sca-1+ cell line derivation and high-throughput
cell sorting from infarcted hearts
To derive the Sca-1+ line, normal hearts (five animals/group) were
excised and immediately processed. Isolation was performed by using
the Cardiac Stem Cells Isolation kit (Millipore, Billerica, MA, USA),
according to Manufacturer’s instruction. Following isolation, cells were
maintained in cardiac Stem Cell Maintenance Medium (Millipore). For
isolation of Sca-1+/CD45+/ cells, a flow cytometry-based sorting
method was adopted. Briefly, myocardial tissue was digested to obtain
a single cell suspension, then labelled with anti Sca-1 and anti CD45
antibodies and finally sorted by using a BD FACSAria IITM Flow-Sorter.
Further details about derivation, differentiation and functional character-
ization of these cells are provided in the online Data S1.
Histology/Immunofluorescence
Left Ventricle Transversal sections of paraffin-embedded hearts (five
animals/group/time-point) were de-waxed and re-hydrated with conven-
tional ethanol series. Gross morphology of the LV wall was revealed by
haematoxylin/eosin staining followed by image acquisition under an
Axioskop light microscope (Zeiss Italia, Arese, Italy) equipped with a
high-resolution digital camera. For IF imaging, de-waxed slides were
treated for antigen retrieval, followed by incubation with blocking and
primary/secondary antibodies solutions. Three/four fluorescence-stained
slides were observed with an LSM710 Confocal Microscope (Zeiss).
Further details about histology and IF methods are provided in the
online Data S1.
RNA interference and cell transfection
Validated high-performance purity grade small interfering RNAs (siRNA)
against GPR17 were synthesized by Thermo Scientific Dharmacon by
using the Acell siRNA design algorithm and a proprietary homology
analysis tool. Control siRNA, with a non-silencing oligonucleotide
sequence that does not recognize any known homology to mammalian
genes, was also generated as a negative control. Cells, at 70–80% con-
fluence, were transfected with siRNA by using Accell delivery medium
(Thermo Fisher Scientific, Lafayette, CO, USA). After 24 hrs, the trans-
fection procedure was stopped by cell collection to RNA extraction.
Expression of GPR17 and functional analysis were performed as
described in the online supplementary material.
Statistical analysis
All data are expressed as mean  SEM. Overall comparisons of the
treatment groups were performed by using one-way ANOVA method with
Newman Keuls post-hoc test. In case of one-to-one comparisons, two
tailed unpaired Student’s t-test was used. P values <0.05 value were
considered statistically significant and indicated by * in the figures.
Results
GPR17 is expressed in stromal Sca1+ cells in
normal harts, in Sca-1+/CD31− cells, and in
recruited myeloid cells after MI
To localize cells expressing GPR17 in the mouse heart, an IF staining
with an antibody directed against the GPR17 C-terminal region was
set up. The specificity of this antibody to recognize GPR17 has been
previously determined [18]. The GPR17 staining was initially used in
combination with the cardiac marker a-Sarcomeric Actin (SA) to dis-
criminate between myocytes and non-myocyte cells. The results
(Fig. 1A) identified abundant interstitial cells expressing GPR17;
these cells were found in all heart compartments without a confined
expression. GPR17 antibody staining was then performed in
combination with TRITC-conjugated Isolectin-B4 (Iso-B4), which
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specifically recognizes endothelial cells and macrophages [19, 20]
(Fig. 1B). This showed a clearly non-overlapping expression of
GPR17 in Iso-B4+ cells, thus excluding endothelial or myeloid pheno-
types of GPR17+ cells in the normoxic heart.
To assess the expression of GPR17 in the ischaemic myocardium,
a mouse model of MI by permanent ligation of the LAD coronary
artery was used [17]. As shown in Figure S1, in this model, a burst of
infiltrating cells appeared in the ischaemic areas as early as at 24 after
ischaemia. At this time-point, the presence of GPR17+ cells was
markedly increased, especially at the infarct border zone (Fig. 1C).
Following infarction, a portion of GPR17+ cells also displayed reactiv-
ity with Iso-B4 (Fig. 1D), suggesting a macrophage phenotype.
Finally, the expression of GPR17 was confirmed by RT-PCR in ischae-
mic versus normal hearts (Fig. 1E).
The presence of Adenosine receptor A2B has been recently
reported in Sca-1+/CD31 cardiac cells, implying purinergic signalling
in the regulation of these cells [16]. We therefore hypothesized that
GPR17 may be expressed, before and after ischaemia, in stromal cells
with mesenchymal characteristics [21]. To this aim, an IF analysis
was performed to assess the expression of Sca-1 marker in GPR17+
cells. The results showed that before MI induction the vast majority of
GPR17+ cells expressed Sca-1 (Fig. 2A). Because of their paucity,
cells expressing Sca-1 in the non-ischaemic ventricular tissue could
not be quantified. At 24 and 48 hrs after ischaemia, there was a dra-
matic increase in the number of cells expressing both markers
(Fig. 2B, Fig. S2) and the appearance of GPR17+ cells, which did not
express Sca-1. Irrespectively of Sca-1 expression, GPR17+ cells
appeared located in groups apparently migrating just beneath the liv-
ing myocardial cells. Membrane expression of GPR17 was confirmed
by Z-stack reconstruction of confocal images (Fig. S3).
The appearance in the ischaemic myocardium of GPR17+/Iso-B4+
(Fig. 1D) and GPR17+/Sca-1 (Fig. 2B and Fig. S2) cells suggested
that the receptor characterizes also a circulating inflammatory cells
population recruited at short time after infarction. To substantiate this
finding, we performed a CD45/GPR17 staining. This indicated the
presence of CD45 in groups of GPR17+ cells (Fig. 3A), particularly in
those located below the endocardium layer (Fig. 3A). To quantify the
presence of cells expressing GPR17 in conjunction with the other
considered markers, a cell counting on tissue sections was finally
performed (Fig. S4). This revealed the most abundant cells to be the
GPR17+ followed by those Iso-B4+. By contrast, the Sca-1+ cells were
the less abundant.
To exclude that GPR17+ cells are endothelial cells recruited by
ischaemia in the infarcted myocardium, a CD31 immunostaining was
performed (Fig. 4). This showed the absence of GPR17 and CD31
co-expression in the infiltrating cells at the border zone of the
A B E
C D
Fig. 1 Expression of GPR17 in normal mouse hearts and after infarction. (A and B) Confocal microscopy images of normal mouse hearts histological
sections stained with GPR17, a-Sarc Actin (SA) specific antibodies and TRITC-conjugated Isolectin-B4 (Iso-B4). GPR17 was observed exclusively in
interstitial cells between the myocytes and were not associated with capillaries (c). Arrows indicate the endocardial cells (en) covering the ventricular
cavity, which were also negative for GPR17 in non-ischaemic mice. (C and D) the number of GPR17+ cells was dramatically increased already at
24 hrs after MI in ischaemic areas. GPR17+ cells were also found arterial-like structures (ar, arrows) present in the ischaemic areas. Iso-B4 staining
showed that after MI induction, a population expressing GPR17 and labelled with the Lectin appeared in the ischaemic areas (arrowheads). These
cells were found in association with groups of cells expressing, alternatively, only one of the markers (arrows). (E) RT-PCR analysis of the total
RNA extracted from sham (Sh)-operated versus infarcted (MI) mice showed no changes in GPR17 before and after MI. The 18s rRNA was used as
an internal control.
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ischaemic myocardium, although an immunoreactivity for the recep-
tor was clearly found in the endothelium of arterial-like vessels
(Figs 3B and 4). Taken together, these results suggest that distinct
GPR17+/CD31 cellular populations, one deriving from cardiac stro-
mal cells (neither expressing CD45 nor stained with Iso-B4), and
another from blood-derived inflammatory cells (expressing CD45 and
stained with Iso-B4), are concomitantly recruited in the ischaemic
myocardium.
Cardiac GPR17+/Sca-1+/CD31−/CD45− cells
represent a myo-fibroblast (MF) progenitor cell
population in vivo and in vitro
To determine whether cells expressing GPR17 have cardiac stromal
cells characteristics with the potential to differentiate into MF-like
cells [22], co-staining with CD44 and Collagen-I was performed
(Fig. 3B and Fig. S5). CD44 was present in a high proportion of
GPR17+ cells, while only a non-quantifiable amount of these cells was
found to co-express Collagen-I, suggesting an immature phenotype.
This was confirmed by a time-course of MF-specific marker a-SMA
(Fig. S6), which started being expressed in the scar only 1 week after
infarction [23]. A flow-sorting strategy was then used to separate
Sca-1+/CD45+ from Sca-1+/CD45 cells in the ischaemic heart
(Fig. 5A). Flow-sorted cells were used for RNA extraction, or to
assess differentiation in culture. Results indicated GPR17 expression
in both sorted cellular populations (Fig. 5B). In addition, Sca-1+/
CD45 cells spontaneously differentiated into MFs, as demonstrated
by the presence of polymerized smooth muscle actin fibres (Fig. 5C),
a hallmark of MFs [24]. As the number and the viability of sorted cells
from the ischaemic hearts were not appropriate to perform functional
studies, a cardiac Sca-1+/CD31 cell line was derived by clonal ampli-
fication as already described [21]. Figures S7 and S8, show the prin-
cipal characteristics of these cells. Consistent with previous
characterizations, this cell line expressed high levels of mesenchymal
markers CD29, CD44 and CD105 [21], and displayed a relatively high
percentage of cells extruding the nuclear marker Hoechst 33342 in a
‘side-population’ (SP) flow cytometric assay [25]. Sca-1+ cells did not
express haematopoietic lineage markers and the tyrosine kinase
receptor c-kit (CD117), the marker characterizing cardiac stem cells
and other relevant myocardial-resident cells such as telocytes and
stromal cells in mice [26–31] and humans [32–34] (data not shown).
The expression of GPR17 in these cells was confirmed by IF, flow
cytometry and RNA analyses.
A B
Fig. 2 GPR17+ expression in Sca-1+ cells before and after MI. (A) Staining with SA, Sca-1 and GPR17 antibodies showed that GPR17+ interstitial
cells in the normal heart express the Sca-1 marker (arrowheads). Only occasionally, cells expressing GPR17 were Sca-1. (B) The number of
GPR17+/Sca-1+ cells (arrowheads) in the border zone of the infarct and in the ischaemic areas were elevated at 24 hrs after MI. Interestingly, the
cells expressing, alternatively, only one of the markers were also increased (arrowheads), suggesting a heterogeneous origin. Dashed line indicates
the boundary between the ischaemic and non-ischaemic zone.
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The function of the derived GPR17+/Sca-1+/CD31/CD45 cells
as MF progenitors was assessed in differentiation assays by using a
medium containing transforming growth factor b (TGF-b), a cytokine
playing a pivotal role in activating MFs in the ischaemic heart [4].
Under MF differentiation conditions (Fig. 6), a substantial change in
cellular morphology was observed, with an increase in cell size, the
adoption of a fibroblast morphology and the development of smooth
muscle actin containing stress fibres. Interestingly, treatment with
TGF-b also potently inhibited cell proliferation, shown by a decrease
in the amount of cells expressing the cell-cycle marker Ki67. Flow
cytometry analysis showed that CD44 and GPR17 expression were
maintained at high levels in TGF-b-treated cells, while aSMA was sig-
nificantly up-regulated. Finally, the percentage of Collagen-I+ cells
showed a clear trend to increase, although it did not reach statistical
significance.
GPR17 agonists promote Sca-1+ cells migration
in vitro
The previous results indicated that the clonal cell line could be used
bona fide as a model to investigate GPR17 functions in cardiac stromal
A
B
Fig. 3 Expression of CD45 and CD44 in
subgroups of GPR17+ cells. (A) Panels on
the top left show low magnification of
CD45 marker expression in GPR17+
(arrowheads) and GPR17 (arrows) cells.
The four panels on the bottom left show
that some cellular clusters had a mutually
exclusive expression of the two markers
(* for CD45+ and # for GPR17+ cells). The
high magnification panels on the right
show the presence of CD45+ cells homing
events. These cells (*) adhered to the
endocardium (en, arrows) covering ven-
tricular cavity (VC); note that endocardial
cells in ischaemic mice expressed the
receptor. CD45+ cells expressed GPR17
only after invading the sub-endocardial
tissue (arrowheads). The dashed line indi-
cates the boundary between the ischaemic
and non-ischaemic zone. (B) CD44+ cells
infiltrating the myocardium were observed
at 48 hrs post-MI both in the sub-endo-
thelium and in the ischaemic myocardium.
Cells expressing both markers (arrow-
heads) or, alternatively, one of the mark-
ers were observed. As shown in the upper
right panel, round cells co-expressing
GPR17 and CD44 were found associated
with the endothelium of an arterial-like
vessel (ar) in the ischaemic myocardium.
Note the presence of endothelial cells
expressing GPR17. VC; ventricular cavity.
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cells. Experiments in the presence of agonists such as UDP-Glucose
(100 lM) and LTD4 (100 nM), known to activate the receptor, were
then performed. While neither UDP-Glucose nor LTD4 caused signifi-
cant changes on (i) cell cycle, (ii) hypoxia-induced apoptosis (data not
shown) or (iii) TGF-b-induced cells differentiation, treatment with both
agonists had a potent effect in migration assays (Fig. 7A). Interest-
ingly, the migratory effect was inhibited by adding two GPR17 phar-
macological antagonists, Cangrelor (10 lM) and Montelukast (1 lM).
The direct role of GPR17 in Sca-1+ cells migratory activity was univo-
cally confirmed by siRNA studies, which showed a reduction in the
agonist-dependent cell motility in GPR17 knockout cells (Fig. 7B).
Reduced recruitment of GPR17+ and CD45+, but
not of CD44+, cells in infarcted hearts treated
with P2Y antagonist Cangrelor
Given the involvement of GPR17 in Sca-1+ cells motility in vitro, we
tested whether receptor blockade by antagonists alters the early
recruitment of cells expressing GPR17, MSC (CD44) or myeloid cells
(CD45) markers in vivo. The experiment was performed by pre-
treating mice with Cangrelor followed by direct drug injection into the
infarct border zone. Mice were killed 24 hrs later and the hearts were
A
B C
Fig. 4 Absence of endothelial marker
CD31 in GPR17+ cells invading the ischae-
mic myocardium. (A) a GPR17 immunore-
activity was observed in the endothelium
(en, arrows) of arterial-like vessels pres-
ent in the ischaemic border zone. (B and
C) high-power views of the ischaemia
border zone, showing that GPR17+ cells
(arrowheads) did not show CD31 immu-
noreactivity. This excludes the endothelial
phenotype of GPR17+ cells invading the
myocardium after MI. c: capillaries; ar:
arterial-like vessels.
A
B C
Fig. 5 Expression of GPR17 characterizes
a MF progenitor cell population in the
infarcted heart. (A) Flow cytometry plots
showing the logical gating strategy
adopted to identify and separate Sca-1+/
CD45 from Sca-1+/CD45+ in myocyte-
free mononuclear cell suspension obtained
by enzymatic dissociation of infarcted
hearts at 48 hrs post-MI. (B) Sca-1+/
CD45+ and Sca-1+/CD45 cells were
sorted and analysed by RT-PCR for the
expression of GPR17. (C) Flow-sorted
Sca-1+/CD45 cells underwent spontane-
ous differentiation into MF-like cells, as
revealed by polymerization of aSMA
fibres.
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Fig. 6 Cardiac GPR17+/Sca-1+/CD31/CD45 cells represent a myo-fibroblast (MF) progenitor cell population. (A) the GPR17+/Sca-1+/CD31/
CD45 cell line obtained from normal hearts (Figs S6 and S7) was treated with a differentiation medium (DM) containing TGF-b to induce MF dif-
ferentiation. The treatment caused up-regulation of MF marker aSMA and, although not significantly, Collagen-I. The increase in aSMA expression
was also confirmed by the analysis of the mean fluorescence intensity (MFI), as well as by western blotting. DDR2 expression remained low,
while CD44 did not change. (B) Immunofluorescence with a Ki-67 antibody (upper panels) and aSMA and GPR17 antibodies (lower panels) in
maintenance (MM) and differentiation (DM) media revealed that the stromal cell line acquired MF characteristics as characterized by formation
of aSMA fibres. Differentiation occurred in concert with a reduction in KI-67+ cell number (arrowheads). By contrast, GPR17 was not
down-regulated.
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processed for immunohistochemical detection of the selected mark-
ers (Fig. 7C and D). Cell counting on serial confocal microscope
images of the ischaemic zone showed a reduced presence of infiltrat-
ing GPR17+ and CD45+ cells in drug-treated versus saline-injected
mice. By contrast, the drug did not modify the presence of CD44+
cells (Fig. 7E).
Discussion
The importance of Cys-LTs and purinergic signalling in MI is well
established. Indeed, studies in the early ’90s showed that blockade of
leukotriene synthesis or antagonism of Cys-LT receptor alleviates the
consequences of MI [9, 11]. These data, supported by other findings
using anti-inflammatory agents in animal MI models, have led to the
hypothesis, never confirmed in clinical trials, that modulation of early
inflammatory events might be a feasible way to control the extent of
hypoxic ischemic damage (discussed in [3]). P2 receptors have been
also proposed as potential therapeutic targets in the cardiac ischemia
setting; in particular, the P2X-type receptors with their pleiotropic
functions on cardiac cells ion permeability, or the P2Y-type receptors,
which are coupled to Gq, Gs or Gi proteins and elicit activator or inhib-
itory actions on PLC or adenylate cyclase in a variety of cardiac cells
[35].
GPR17: a receptor preferentially expressed in
resident stromal cells before ischaemia, but
shared in inflammatory cells and cardiac
mesenchymal cells with MF progenitor
characteristics after infarction
GPR17 is a P2Y-like receptor responding to either uracil-nucleotides
and Cys-LTs whose presence characterizes various organs suscepti-
ble to ischaemic damage (e.g. brain, kidney and heart) [12]. Its
peculiar pharmacological profile, initially unveiled in heterologous
expressing systems, has been independently confirmed by some [36,
37], but not other Authors [38]. These contrasting data may be as a
result of dependence of the activity tests on the conditions adopted in
recombinant ‘artificial’ systems, which potentially give rise to
artefacts, especially in the case of constitutive GPR17 activation [39].
On the other hand, GPR17 responses have been more recently fully
confirmed by us [18, 40, 41] and other authors [42] in cells that
natively express the receptors, like oligodendroglia [15, 18, 42] and
PC12 cells [40]. GPR17 has been also reported to act as a negative
regulator of the Cys-LT1 receptor [36, 38]. This suggests that, in
addition to responding to cys-LTs, depending on specific pathophysi-
ological conditions, GPR17 can interact with other closely related
receptors.
GPR17 functions have been mostly addressed in the brain and the
central nervous system, particularly in brain ischaemia or spinal cord
injury models [13, 43–45]. Interestingly, it was found that in vivo
modulation of GPR17 by pharmacological or genetic targeting
improves the outcome of these injuries, suggesting a central role of
the receptor in nervous tissue damage sensing, healing and repair
[13, 45]. By contrast, except for studies addressing the expression at
transcriptional level [12], no further indication has been provided con-
cerning the identity of cells expressing the receptor in the normal
heart and, most importantly, whether GPR17 is modulated following
induction of MI.
The first part of the present study was therefore designed to
address this crucial point. We found that before MI induction, the
most abundant cells expressing GPR17 were located in the intersti-
tium between adjacent cardiac myocytes. These cells were distributed
in the ventricular myocardium without a preferential location and were
not grouped into cellular clusters resembling the typical cardiac stem
cell ‘niches’ [46, 47]. As the majority of cells expressing GPR17 in
non-injured hearts displayed Sca-1 but not Iso-B4 Lectin staining
(Figs 1A, B and 2A), we conclude that in normal conditions, the
receptor characterizes a unique population of cardiac-resident stromal
Fig. 7 GPR17 promotes migration of Sca-1+ cells in vitro and in vivo. (A) A transwell-based migration assay was used to assess the ability of
GPR17 agonists LTD4 [L] and UDP-Glucose [U] (purity ≥97% for LTD4 and ≥98% for UDP-Gluc) to induce Sca-1+ cells migration. FBS was used
as a positive control, while treatments with Montelukast [M] and Cangrelor [C] were used to revert the agonists effect on migration. * indicates sig-
nificant differences (P < 0.05) in the migration level of Sca-1+ cells in the presence of FBS, LTD4 and UDP-Glucose versus cells treated with the
GPR17 antagonists Montelukast and Cangrelor, or the combined agonist+antagonist treatment (L+M; U+C); data were compared by one-way ANOVA
with Newman-Keuls post-hoc analysis (n > 4). $ indicates significant differences in the migration level of Sca-1+ cells in the presence of FBS and
GPR17 agonists (LTD4 and UDP-Glucose versus cells maintained in serum-free medium during migration (negative control). (B) Reduction of Sca-
1+ cells migration in the presence of small interfering RNAs (siRNA) against GPR17. The RT-PCR on the left shows a reduction in GPR17 expres-
sion at 48 hrs after siRNA transfection. Graph on the right indicates the migration index of siRNA treated cells compared to controls. As shown,
GPR17 down-regulation had an overall effect on Sca-1+ cells motility. On the other hand, receptor down-regulation abolished the migratory activity
elicited by LTD4 treatment and reduced, although not significantly, the migration induced by UDP-Glucose. $ indicates a P < 0.05 significance level
by paired t-test comparisons of migration observed in Control siRNA and GPR17-siRNA cells in the indicated conditions (n = 4). * indicates a
P < 0.05 significance level by comparing migration observed in Control siRNA versus GPR17-siRNA in the indicated conditions using unpaired t-test
(n = 4). (C and D) Immunofluorescence detection of GPR17, CD44 and CD45 expressing cells in sections of infarcted mice treated with saline (C)
or Cangrelor (D). (E) In vivo recruitment of GPR17+ and CD45+, but not of CD44+ cells in vivo was reduced by Cangrelor treatment. Data in the
bar graph are expressed as percentages of marker+ cells/total cell number. Images were acquired and analysed by a double-blind analysis proce-
dure. * indicates P < 0.05 by unpaired t-test; n > 20 independent images on saline-injected (n = 3) or Cangrelor-injected (n = 3) infarcted hearts
stained with GPR17/CD44 or GPR17/CD45 antibody mixture.
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cells that does not display endothelial or myeloid characteristics. This
establishes a striking similarity between the heart and the central ner-
vous system, where GPR17+ cells may have a role of damage ‘sensor’
able to activate healing programmes [43].
After the induction of ischaemia, GPR17 was found in at least two
distinct populations. The first is represented by Iso-B4+ or CD45+
myeloid cells, probably recruited from peripheral circulation to the is-
chaemic tissue (Figs 1C, D and 3A); the other, characterized by Sca-1
and negative for CD31, probably deriving from an intra-cardiac stro-
mal cells store (Fig. 4). This hypothesis is supported by the previous
observations that myocardial infarction determines an increase in the
amount of Sca-1+/CD31 cells [48], and recruitment of a multipotent
cardiac MSC population which contributes to cardiac fibrosis [22].
Particularly interesting appeared, in this respect, also the expression
of CD44 in GPR17+ cells in the infarct tissue (Fig. 3B) and the lack of
mature MF marker aSMA at early times after MI, suggesting an
immature phenotype. In fact, expression of CD44, in the presence or
the absence of CD45, was the principal criterion to discriminate
between inflammatory cells homing in the infarcted myocardium from
peripheral circulation and stromal progenitors recruited from heart-
resident pools [22]. For technical reasons (need of performing indi-
rect GPR17 staining of living cells in conjunction with multicolour
membrane marker analysis), it was not possible to proceed with a
direct flow-sorting experiment of GPR17+/Sca-1+/CD44+/CD31/
CD45 cells from infarcted hearts to resolve the cardiac MSC pheno-
type and the MF differentiation potency of the GPR17+ expressing
cells in the infarct. On the other hand, the finding that Sca-1+/CD45
cells sorted from infarcted mice (Fig. 5) and that GPR17+/Sca-1+/
CD31/CD45 cells cloned from the normal hearts (Fig. 6) expressed
high levels of CD44 and were induced by TGF-b treatment to differen-
tiate into cells with enhanced expression and intracellular polymeriza-
tion of aSMA protein, strongly suggest the identity of the observed
GPR17+/CD44+ cells in the ischaemic myocardium (Fig. 3B) as heart-
resident MSCs, endowed with MF differentiation potency. This latter
conclusion is also supported by the absence of c-kit, a marker typical
of cardiac-resident stem cells in mice and humans [26, 32] and of
other stromal cells such as telocytes [28, 30].
Possible function of GPR17 in cardiac-resident
MF progenitors
Cys-LTs and purines are well-established initiators of the inflamma-
tory responses. Their role is that of a ‘find-me signal’ attracting the
phagocytes to sites of apoptotic cells clearance [49] and inducing a
chemokine ‘milieu’ necessary for sequential chemo-attractant cas-
cades involved in pro- inflammatory phases associated with tissue
damage, innate host-defence, and autoimmunity [50]. Prompted by
our preliminary investigations showing that blockade of Cys-LTs
signalling alleviates the extent of hypoxic stress-related cardiac
fibrosis [51], and other reports suggesting the relevance of Adeno-
sine signalling in the protective function of cardiac stromal cells
[16], we determined the function of GPR17 in the cloned cardiac
Sca-1+/CD31 line. While the treatment of the cells with known
Cys-LT/purinergic agonists (LTD4 and UDP-gluc) in vitro did not
have an effect on proliferation and hypoxia-induced apoptosis (data
not shown), both ligands exerted a potent chemotactic effect via
GPR17 activation. This was shown by reversion of the migratory
effect by co-treatment with known GPR17 pharmacological antago-
nists such as Montelukast and Cangrelor, as well as by a more
specific siRNA knockout approach (Fig. 7). In our experiments, we
also investigated whether treatment with the two ligands deter-
mined modifications in the TGF-b-induced MF differentiation pro-
gramme. However, we did not observe remarkable differences (data
not shown). Altogether, these findings point to a specific GPR17 role
in chemotactic guidance of stromal cells towards the ischaemic sites.
A preliminary assessment of a possible in vivo GPR17 function
was provided by treating infarcted mice with systemic and intra-myo-
cardial injection of the GPR17 antagonist Cangrelor, followed by
analysis of the principal cell types recruited in the forming scar
(Fig. 7). The blockade of purinergic signalling transmission by Cangr-
elor led to an interesting and unexpected imbalance between the
amount of the recruited cells in control versus treated mice. In fact,
Cangrelor treatment determined a significant reduction in the number
of GPR17+ cells and myeloid cells, characterized by CD45 expression,
but not that of CD44+ cells (Fig. 7). As Cangrelor targets the puriner-
gic, but not the Cys-LT GPR17 signal transduction pathway, this sug-
gests the existence of redundant mechanisms, possibly linked to the
dual receptor GPR17 nature. Alternatively, an antagonistic function of
GPR17 signalling in distinct stromal and myeloid cells may justify the
observed imbalance between cardiac-derived versus blood-derived
infiltrating cells.
In summary, our results suggest a potential role of the Purinergic
and Cys-LT GPR17 receptor in the early response of cardiac stromal
cells to ischaemia. This is in agreement with a very recent study
showing the involvement of the Adenosine A2B receptor in cardiopro-
tection by Sca-1+ stromal cells [52]. Whether selective modulation of
GPR17 signalling in cardiac-resident stromal cells translates into ben-
eficial treatments to reduce the extent of myocardial fibrosis and to
limit the functional consequences of heart ischaemia is still a matter
of speculation, and it is the subject of our current analyses.
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Figure S1. Left ventricle transversal sections showing the infract
region at 24 and 48 hrs after ligation of the coronary artery.
Figure S2. Evaluation of GPR17+ and Sca-1+ cell populations at
48 hrs after MI by immunofluorescence analysis of transversal
sections (see Fig. S1 for sections orientation) of the ischaemic
LV zones.
Figure S3. Z-stack confocal image of the ischaemic myocar-
dium 24 hrs after ischaemia.
Figure S4. Counting of cells single positive (A) or double/triple
positive (B) cells for the indicated markers, after staining with
multicolour immunofluorescence and confocal analysis.
Figure S5. GPR17+/CD44+ cells invading the infracted myocardium
do not express mature MF marker Collagen-I.
Figure S6. Immunofluorescence showing expression of GPR17
in conjunction with mature myofibroblasts marker aSMA in the
ischaemic myocardium at 48 hrs (48h; upper panels) and
1 week (1W; lower panels) after MI.
Figure S7. Phenotypic characterization of Sca-1+ cell line.
Figure S8. Stability of the Sca-1+ cells line and quantification of
mesenchymal marker expression.
Data S1. Detailed materials and methods.
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